TY - JOUR T1 - Association between ABO blood groups and clinical outcome of coronavirus disease 2019: Evidence from two cohorts JF - medRxiv DO - 10.1101/2020.04.15.20063107 SP - 2020.04.15.20063107 AU - Xianfei Zeng AU - Hongyan Fan AU - Dongxue Lu AU - Fang Huang AU - Xi Meng AU - Zhuo Li AU - Mei Tang AU - Jing Zhang AU - Nannan Liu AU - Zhixin Liu AU - Jingya Zhao AU - Wen Yin AU - Qunxing An AU - Xijing Zhang AU - Xingbin Hu Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/17/2020.04.15.20063107.abstract N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the third most common coronavirus that causes large-scale infections worldwide. The correlations between pathogen susceptibility and blood type distribution have attracted attention decades ago. The current retrospective study aimed to examine the correlation between blood type distribution and SARS-CoV-2 infection, progression, and prognosis in patients with coronavirus disease 2019 (COVID-19). With 265 patients from multiple medical centers and two established cohorts, we found that the blood type A population was more sensitive to SARS-CoV-2. Moreover, the blood type distribution was not relevant to acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), and mortality in COVID-19 patients. These findings are indicative of coping with the great threat since it probed the relationship between blood types and ARDS, AKI, and mortality, in addition to susceptibility in COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding support.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study are included in this article. ER -